Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vir Says Its Best-In-Class COVID-19 Antibody Profile Is Holding Up

Executive Summary

Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.

You may also be interested in...



Can Vir/GSK’s COVID-19 Antibody Prove Its Worth In Early Disease?

Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.

Regeneron And Lilly Are Back With Better COVID-19 Antibody Data – But Still Face Medical Skepticism

After disappointing initially, Lilly and Regeneron are back with compelling data for their monoclonal antibody products, but still face challenges from new COVID-19 variants and medical skepticism.

Coronavirus Update: No Sign Of Agreement In EU's Bitter Row With AstraZeneca Over Vaccine Supplies

The dispute over a likely 60% reduction in supplies of AstraZeneca's COVID-19 vaccine shows no sign of resolution. Meanwhile, Lilly, Vir/GSK team up on COVID-19 antibody combination and Moderna negotiates sale of 100 million additional vaccine doses to US.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel